The latter finding points to a novel mechanism to counteract pulmonary hypertension and implicates a potential therapeutic usage of KCa2.3/KCa3.1 activators for the treatment of pulmonary hypertension. This evidence concerns the gene KCNN4 and pulmonary hypertension.